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Abstract 
We describe the case of a patient who pre-
sented  with  a  right-sided  glomus  jugulare
tumor  and  bilateral  glomus  vagale  tumors.
These  proved  to  be  nonmalignant  paragan-
gliomas on histopathological analysis. Genetic
analysis  revealed  a  germline  heterozygous
missense mutation (Pro81Leu) in the succi-
nate dehydrogenase subunit D (SDHD) gene.
We discuss the clinical presentations of the
familial  paraganglioma  syndrome  type  1,
which is caused by mutations in SDHD, and
the implications for the clinical diagnosis and
care of such patients.
Case Report
A  35-year  old  lady  presented  with  right-
sided pulsatile tinnitus, conductive deafness,
and a vascular lesion in the floor of the right
external  auditory  meatus.  Magnetic  reso-
nance imaging revealed a right-sided glomus
jugulare  tumor  and  bilateral  glomus  vagale
tumors (Figure 1). Both her paternal grandfa-
ther and her father had undergone neck sur-
gery for tumors. She was an only child and had
a  two-year-old  son.  She  was  normotensive,
with no clinical features of von Hippel-Lindau
(VHL) syndrome or neurofibromatosis type 1
(NF1). Serum calcium, urine catecholamine
excretion, and serum calcitonin were within
normal  limits.  Radiolabeled  metaiodobenzyl-
guanidine scanning and MRI imaging of her
abdomen  did  not  demonstrate  any  intra-
abdominal  paragangliomas.  She  underwent
partial excision of her right glomus jugulare
tumor, with complete excision of both the glo-
mus vagale tumors. Histology showed nonma-
lignant paragangliomas. Genomic DNA analy-
sis  revealed  a  germline  heterozygous  mis-
sense mutation (p.Pro81Leu) in exon 3 of the
succinate dehydrogenase subunit D (SDHD)
gene.  Therefore  she  was  diagnosed  with
familial  paraganglioma  syndrome  type  1
(PGL1). 
Discussion
Paragangliomas  are  neuroendocrine
tumors  of  the  autonomic  nervous  system.
Abdominal  and  thoracic  paragangliomas  are
derived from sympathetic tissue and secrete
catecholamines,  like  pheochromocytomas,
which are derived from the adrenal medulla.
Head  and  neck  paragangliomas  are  derived
from  parasympathetic  tissue  and  usually  do
not secrete catecholamines.
1 Up to a third of
paragangliomas and pheochromoctyomas are
associated with hereditary causes; i.e., muta-
tions  in  VHL,  RET (causing  multiple  endo  -
crine neoplasia type 2A-MEN2A), NF1, and the
SDH complex genes SDHB, -C and -D.
2
The  SDH  complex  is  bound  to  the  inner
mitochondrial membrane and participates in
both  the  electron-transport  chain  and  the
Krebs cycle as part of complex II. It consists of
four subunits A-D. Mutations in subunits B, C,
and  D  are  associated  with  hereditary
pheochromocytomas and paragangliomas: the
PGL1  syndrome  with  mutations  in  SDHD,
PGL3 with mutations in SDHC, and PGL4 with
mutations in SDHB.
Multiple mechanisms have been implicated
in  the  pathogenesis  of  SDH  subunit-related
tumors. These include abnormal activation of
hypoxia-inducible  pathways,  producing  a
pseudohypoxic  state  similar  to  that  seen  in
tumors from patients with VHL disease.
3,4 The
HIF-1  and  HIF-2  transcription  factors  are
major mediators of the hypoxic gene response
and the HIF-α subunits are rapidly degraded
in normoxic cells via a VHL protein (pVHL)-
dependent  mechanism.
5 Activation  of  HIF
pathways with SDH subunit inactivation has
been linked to accumulation of succinate and
resulting inhibition of the prolyl hydroxylase
enzymes that are necessary for HIF-α subunit
modification and proteosomal degradation, as
pVHL is unable to bind the unmodified sub-
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Figure 1. Magnetic resonance
image  scan  of  the  neck.  Fast
T2-weighted  MRI  scan
demonstrates the right glomus
jugulare  tumor  (adjacent  to
right  cochlea,  arrow),  and
bilateral glomus vagale tumors
(arrows).[Rare Tumors 2009; 1:e29] [page 89]
units.
4 In  addition,  animal  models  of  SDH
inactivation  suggest  that  reactive  oxygen
species may be increased and also might pro-
voke  a  pseudohypoxic  state.
6 Therefore
SDHB/D mutations may predispose to a failure
of normal developmental apoptosis of sympa-
thetic neuronal cells leading to persistence of
“pheochromocytoma precursor cells”.
5 PGL1/
SDHD disease is inherited as an autosomal
dominant  trait,  but  demonstrates  parent-of-
origin  effects  in  that  tumors  only  develop
when  the  mutation  is  inherited  from  the
father,  with  possible  rare  exceptions.
6
Typically, head and neck paragangliomas are
found, but pheochromocytomas and abdomi-
nal  or  thoracic  paragangliomas  can  develop
also. The tumors often are multiple, and tend
to develop early, with a median age of first
presentation of 31 years. In addition, there is
an  age-dependent  penetrance,  with  48  per-
cent, 73 percent, and 100 percent being diag-
nosed  by  the  ages  of  30,  40,  and  70  years,
respectively.
7 In  contrast  to  PGL4/SDHB dis-
ease,  where  metastatic  disease  is  common,
the tumors in PGL1 tend to be benign.
7
Conclusions
The  clinical  data  accumulated  regarding
familial paraganglioma syndromes raise sev-
eral important implications for their clinical
management.
• Firstly,  patients  with  familial  disease  or
multiple tumors should be offered genetic
testing.  In  addition,  individuals  with
apparently sporadic pheochromocytoma or
paraganglioma disease will require genetic
screening  if  risk  factors  such  as  extra-
adrenal  sympathetic  paraganglioma,
malignant paraganglioma, or young age at
diagnosis (e.g., below 40 years) are pres-
ent.
2 Depending on the clinical presenta-
tion,  mutation  analysis  of  VHL,  SDHB,
SDHC,  SDHD,  and/or  RET genes  may  be
indicated. 
• Secondly, the relatives of patients in whom
a pathogenic mutation is detected should
be offered genetic screening, even if they
are  asymptomatic,  because  of  the  age-
dependent  penetrance.  The  inheritance
pattern of PGL1-related disease will influ-
ence  the  screening  program  (see  follow-
ing) and the counseling given to patients
and their relatives. In our patient’s case,
her  son  is  not  likely  to  develop  tumors
because  of  the  parent-of-origin  effect  on
penetrance.  However,  he  will  require
genetic  screening  when  he  is  older,
because  if  he  is  a  carrier  of  the  SDHD
mutation, then his children may be at risk. 
• Thirdly,  carriers  of  these  mutations  will
require regular, lifelong, clinical, biochem-
ical, and radiological screening. In order to
reduce  the  lifetime  exposure  to  ionizing
radiation, it is necessary to use imaging
modalities such as MRI or ultrasound.
Optimum  clinical  management  requires
the  multidisciplinary  expertise  of  sur-
geons,  endocrinologists,  clinical  geneti-
cists, and radiologists.
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